Safety of etanercept in elderly subjects with rheumatoid arthritis

Alfredomaria Lurati
Mariagrazia Marrazza
Katia Angela
Magda Scarpellini
Fornaroli hospital, Rheumatology Unit, Magenta, Italy

Objective: To report side effects seen in a clinical cohort of patients aged >65 years with rheumatoid arthritis (RA) treated with the tumor necrosis factor-α TNF-α blocker etanercept and to compare the side effects rate with patients aged ≤65 years.

Methods: All patients with RA that started etanercept and who were referred to our rheumatology unit from November 2005 to March 2009 were included in this study and prospectively followed to collect side effects related to therapy.

Results: One hundred three patients were enrolled: 41 (37 females, 4 males) aged >65 years and 62 (40 females, 22 males) aged ≤65 years. In the patients aged >65 years, the safety profile (defined as rate of side effects) of etanercept was similar to that in patients aged ≤65 years (P > 0.05) and the survival curves between the groups were similar (P > 0.05).

Conclusions: In our three-year experience, the anti-TNFα agent etanercept has been well tolerated and safe in elderly patients. The risk of side effects in these patients was no greater than in subjects aged ≤65 years. However, such inhibitors are associated with various and numerous side effects and elderly patients with RA should be carefully monitored to limit the risk of side effects during anti-TNFα therapy as much as possible.

Keywords: anti-TNF therapy, rheumatoid arthritis, elderly

Introduction

Rheumatoid arthritis (RA) is an erosive disease that predominantly involves the synovial tissue of joints and is characterized by variable disease onset and clinical course, potentially resulting in structural joint destruction and subsequent permanent disability.1

Epidemiological studies have shown that RA is most prevalent in those who are aged 65 years or older.2,3 The disease is commonly diagnosed between the ages of 30 and 50 years, but up to 33% of subjects may be diagnosed after the age of 60 years. Despite the high prevalence of RA in the elderly, and the likelihood that older patients have adverse reactions to medications as a result of age-related changes in drug metabolism and the presence of comorbid illnesses requiring concomitant medications, patients older than 65 years tend to be inadequately represented in RA clinical trials.5,6 Also, the tolerability of and response to therapy in these patients as a group has not been studied in detail. In one retrospective analysis of disease-modifying antirheumatic drugs (DMARDs) including gold, D-penicillamine, azathioprine, and methotrexate (MTX), a substantially higher withdrawal rate due to toxicity was observed in patients older than 65 years compared to those younger than 65 years.5
Etanercept is a recombinant human fusion protein that inhibits the activity of tumor necrosis factor (TNF) and lymphotoxin-α. In clinical trials of RA, etanercept alone or in combination with MTX was well tolerated and produced significant sustained improvement in disease activity in patients with long-standing RA who failed multiple DMARDs and in patients with early aggressive disease who never received MTX. Etanercept is effective in inhibiting radiographic progression in patients with RA; 72% of patients with early aggressive RA who received 25 mg etanercept monotherapy had no new radiographic erosions during one year of treatment. In these clinical trials, the response to etanercept therapy in elderly patients was not described in detail.

The aim of our study was to assess whether the use of etanercept is associated with a different rate of adverse events in elderly versus younger RA subjects and whether the drug survival curves are different in the two groups.

Materials and methods

Subjects with RA (American College of Rheumatology criteria) that started etanercept from November 2005 to March 2009 and referring to our rheumatology unit were included in this study and prospectively followed. The etanercept dose was 50 mg subcutaneously once a week. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, if needed, MTX, or other previous DMARDs, if tolerated, were continued. A complete physical examination, standard laboratory tests, were assessed at baseline and either every two months thereafter. At the screening visit a chest X-ray, an electrocardiogram (EKG), a tuberculin skin test were performed and a complete hematic biometry analysis (complete blood count, C-reactive protein, erythrocyte sedimentation rate, creatinine, prostate-specific antigen total and free, aspartate aminotransferase and alanine aminotransferase, antinuclear antibodies, urinalysis). Patients aged >65 years also received an abdominal ecography, a mammography, three serial stool blood tests, and serum electrophoresis. A previous malignancy, history of cardiac failure with New York Heart Association (NYHA) class ≥3, or clinical findings suspect for malignancies at the study screening were used as exclusion criteria. Safety profile points included incidence rates of all side effects (SEs) defined as: adverse events (AE, with a temporary therapy suspension), serious AE (SAE, defined as an AE that required the definitive discontinuation of the therapy and hospitalization, malignancies, and deaths), infectious diseases (IAE, with temporary or definitive therapy suspension associated with intravenous antibiotic treatment).

Statistical analysis

Pairwise comparisons were based on the Wilcoxon matched pairs signed-ranks test. The safety profile in the two groups was estimated by survival analysis, taking any AE as the event of interest using the Kaplan–Meier method. Comparisons between the resultant curves were made by log rank test. All values of <0.05 were considered to indicate statistical significance (two-tailed test).

Results

One hundred three caucasian patients out of 254 were eligible: 41 (37 females, 4 males) aged >65 years and 62 (40 females, 22 males) aged <65 years. Mean disease onset age was 57.4 ± 1.7 years in younger and 60.4 ± 3.2 years in older patients (P = 0.05). Mean age at beginning of TNF blocker was 57.8 ± 6.9 years in younger and 68.2 ± 3.2 years in older patients (P < 0.05). The duration of the anti-TNF treatment was 29.4 ± 1.2 months and 27.9 ± 3.3 months, respectively (P = 0.05). In the whole population, 35 SEs (33.98% of cases) that led to temporary/permanent withdrawal were observed (9 AEs, 20 IAEs, 6 SAEs). The rate of patients presenting SEs was 41.4% of patients aged >65 years versus 30.6% of patients aged ≤65 years (P = 0.318; Table 1). The survival curves of these two groups were no significantly different (Mantel–Cox log rank test, P = 0.267; Figure 1).

Table 1 Number of adverse events in the groups

<table>
<thead>
<tr>
<th># Adverse events (AEs)</th>
<th>≤65 years old patients #62</th>
<th>&gt;65 year old patients #41</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Local reaction</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Flu</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td># Infectious diseases (IAE)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower Urinary tract infections</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Upper Respiratory tract infection</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Tonsillitis</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Discitis</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Mycotic infection</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Herpes virus infection</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td># Serious adverse events (SAEs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Squamouscellar carcinoma</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>MGUS</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Cardiac failure</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Total AEs</td>
<td>19</td>
<td>17</td>
</tr>
</tbody>
</table>
tissue responsiveness, and homeostatic mechanisms,17–19 These factors may contribute to differences in toxicity and efficacy among different age groups in patients with RA. We observed no consistent differences in the rates or types of adverse events between the age groups in this study, which suggests that treatment with etanercept does not increase the risk of these events in the elderly population beyond the increases inherent with advanced age and comorbidities.

Disclosures
The authors report no conflicts of interest in this work.

References
1. Hochberg MC. Predicting the prognosis of patients with rheumatoid arthritis: is there a crystal ball? J Rheumatol. 1993;20:1265–1267.

